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Abstract
Background: The metabolic syndrome together with insulin resistance and their consequences
are basic factors in pathogenesis of atherosclerosis. Chronic infections with herpes simplex virus
type 1 (HSV-1), cytomegalovirus (CMV), and Chlamydia pneumoniae are associated with the
development of atherosclerosis and coronary heart disease. The infectious aspects of metabolic
syndrome have not been investigated.
Methods: In a cross-sectional, population-based study, we used National Cholesterol Education
Program (NCEP)-Adult Treatment Panel (ATP)-III criteria in 1791 subjects, aged 25 years and over,
selected by cluster random sampling in three Iranian ports in the northern Persian Gulf. Sera were
analyzed for IgG antibodies to Chlamydia pneumoniae, HSV-1, Helicobacter pylori (H. pylori) and
CMV using ELISA.
Results: In multiple logistic regression analysis, of the infectious agents, CMV [OR = 1.81 (1.05–
3.10); p = 0.03], H. pylori [OR = 1.50 (1.12–2.00); p = 0.007] and Chlamydia pneumoniae [OR =
1.69 (1.27–2.25); p < 0.0001] showed a significant association with the metabolic syndrome in men
and HSV-1 [OR = 1.95 (1.22–3.11); p = 0.005], H. pylori [OR = 1.45 (1.09–1.94); 0.01] and
Chlamydia pneumoniae [OR = 1.65 (1.23–2.21); p = 0.001] in women.
Conclusion: The metabolic syndrome, which occurs very frequently in the general population, has
a significant association with prior infection with Chlamydia pneumoniae, Helicobacter pylori,
cytomegalovirus and herpes simplex virus type 1. Hypothesis about participation of infection in
pathogenesis of metabolic syndrome should be investigated.
Background
The metabolic syndrome is said to consist of a cluster of
heart disease risk factors, including low high density lipo-
protein cholesterol, high triglycerides, impaired carbohy-
drate metabolism, central obesity, and high blood
pressure [1,2]. The metabolic syndrome is expected to be
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diagnosed in millions of subjects in the near future world-
wide by either WHO or NCEP-ATPIII criteria [3]. Coro-
nary heart disease (CHD), cardiovascular disease (CVD),
and total mortality are significantly higher in adults with
than in those without metabolic syndrome [4]. The meta-
bolic syndrome is a pro-inflammatory state as evidenced
by increased levels of IL-6, TNF-α, and C-reactive protein
(CRP), serum amyloid A, and leptin and lower level of
adiponectin. Each of the features of the metabolic syn-
drome in effect contributes to this pro-inflammatory state
[5].
Animal/experimental, pathological, and cross-sectional
seroepidemiological studies conducted among middle-
aged populations provide some support for the hypothe-
sis that infections with herpes simplex virus type 1 (HSV-
1), cytomegalovirus (CMV), and Chlamydia pneumoniae
are associated with the development of atherosclerosis
and coronary heart disease [6].
Infectious agents can contribute to the acceleration of
atherosclerosis development by nonspecific mechanisms,
such as hypercoagulation, increased production of adhe-
sion molecules, and elevated C-reactive protein (CRP) lev-
els [7].
Given both the high prevalence of IgG antibodies to her-
pes simplex virus type 1 (HSV-1), cytomegalovirus
(CMV), and Chlamydia pneumoniae and the high preva-
lence of metabolic syndrome among adults, it is particu-
larly important to determine whether serological evidence
of prior infection with these agents is associated with met-
abolic syndrome. We examined this question in an ancil-
lary study to the Persian Gulf Healthy Heart Study, a
cohort study of men and women aged ≥ 25 years.
Materials and methods
The Persian Gulf Healthy Heart Study is a study to deter-
mine the risk factors for cardiovascular diseases among
the Northern Persian Gulf population (Bushehr and Hor-
mozghan Provinces) and to develop community-based
interventional projects to change the lifestyles of the pop-
ulation and to present the rising threat of CVD in the
region. The design of this study encompasses two major
components: phase I is a cross-sectional prevalence study
of unhealthy lifestyle and ischemic heart disease (IHD)
and associated risk factors and phase II is a multiple inter-
ventional project for reduction of CVD in the region.
Community sampling and baseline examinations
In phase I of the study, a multiple-stage stratified cluster
random sampling technique was used to select 3000 peo-
ple aged >= 25 years from major ports of Bushehr Prov-
ince (an Iranian province with the greatest boarder with
the Persian Gulf). The studied ports of the Northern Per-
sian Gulf were Bushehr Port (the center of Bushehr Prov-
ince, with a population of 150000 and coronary events of
481.05 and 156.61 per 100,000 for men and women;
respectively), Genaveh and Deilam Ports. Specifications
dictated that approximately two persons per selected
household could be included in phase I cross-sectional
survey.
Examinations were conducted in 2003–04. All subjects
were asked to fast and to present to the survey center
between 7.30–9.30 a.m. Blood pressure was assessed
twice at the right arm after a 15-min rest in the sitting posi-
tion, using a standard mercury sphygmomanometer.
Waist circumference was defined at the midway level
between the costal margins and the iliac crests. Hip cir-
cumference was measured at the level of the greater tro-
chanters.
A fasting blood sample was taken, all samples were
promptly centrifuged, separated and analyses were carried
out at the Persian Gulf Health Research Center on the day
of blood collection using a Selectra 2 autoanalyzer (Vital
Scientific, Spankeren, The Netherlands). Glucose was
assayed by enzymatic (glucose oxidase) colorimetric
method using a commercial kit (Pars Azmun Inc; Tehran,
Iran). Serum total cholesterol and HDL-cholesterol were
measured using a cholesterol oxidase phenol aminoanti-
pyrine and triglycerides using a glycerol-3 phosphate oxi-
dase phenol aminoantipyrine enzymatic method. Serum
LDL-cholesterol was calculated using the Friedwald for-
mula; LDL-cholesterol was not calculated when triglycer-
ides concentration was >400 mg/dl.
The metabolic syndrome was diagnosed with the criteria
indicated by the NCEP-ATP III [8]. According to these cri-
teria, subjects with the metabolic syndrome are those with
any combination of three or more of the following risk
determinants: fasting plasma glucose >= 6.1 mmol/l,
blood pressure >= 130/>= 85 mmHg or antihypertensive
treatment, plasma triglycerides >= 1.7 mmol/l, plasma
HDL cholesterol < 1.03 mmol/l in men and < 1.29 mmol/
l in women, and waist circumference >102 cm in men or
>88 cm in women.
Serology
IgG antibodies against Chlamydia pneumoniae were
measured by a commercial test kit (DRG Instruments
GmbH, Germany). The principle of the kit was based on
an indirect solid-phase enzyme immunoassay with horse-
radish peroxidase as a marker enzyme; the positivity
threshold was enzyme immunounits (EIU) >45. Sera were
screened for IgG antibodies against herpes simplex virus
type 1, cytomegalovirus and Helicobacter pylori with an
ELISA (RADIM SpA, Italia), and the samples were consid-
ered positive with IgG values higher than 30 RU/ml forCardiovascular Diabetology 2006, 5:25 http://www.cardiab.com/content/5/1/25
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CMV and H. pylori. Samples with optical density higher
than cut-off control were considered reactive for anti-HSV
type 1 IgG antibodies.
Statistical methods
For analysis of data, the studied population was divided
into four groups: 25–34, 35–44, 45–54, and 55–64 years
of age. Odds ratios (ORs) estimating the association of
metabolic syndrome with presence of IgG antibodies
against infectious agents were calculated.
Multiple logistic regression analysis was used to ascertain
the associations between metabolic syndrome and pres-
ence of IgG antibodies against infectious agents when the
presence of IgG antibodies against infectious agents con-
sidered as independent covariates and simultaneously
included into the same equation, with metabolic syn-
drome as the dependent variable. P < 0.05 was considered
statistically significant.
Statistical analysis was performed with an IBM computer
using the SPSS 9.05 statistical software package (SPSS Inc.,
Chicago, IL).
Results
A total of 1791 (49.2% males, 50.8% females) of the stud-
ied population were evaluated for IgG HSV-1, CMV, H.
pylori and Chlamydia pneumoniae. Of the studied sub-
jects, 36.1% was between 25–34 years, 29.0% between
35–44 years, 21.9% between 45–54 years, and 12.7%
between 55–66 years.
A total of 52.1% of the subjects (54.6% of males & 49.9%
of females; p = 0.005) had clinical traits of the metabolic
syndrome as defined by ATP III criteria. The prevalence of
metabolic syndrome was increased with increasing in age
(p = 0.0001).
Table 1 shows prevalence of IgG antibodies against HSV-
1, Chlamydia pneumoniae, HSV-1 and H. pylori among
men & women with and without the metabolic syndrome.
The prevalence of IgG antibodies against Chlamydia
pneumoniae was higher in men (45.7%) than women
(35.8%) (p < 0.0001); the prevalence of IgG antibodies
against HSV-1 was lower in men (83.8%) than women
(88.6%) but no significant differences was observed in
prevalence of IgG antibodies against CMV and H. pylori in
men (92.0%, 62.9%, respectively) and women (94.2%
and 59.6%, respectively). There was an increase in IgG
antibodies against herpes simplex virus type 1 (HSV-1), H.
pylori and Chlamydia pneumoniae with increasing age in
both sexes (p = 0.0001) but the increase in prevalence of
IgG antibodies against CMV with increasing in age was
observed only in men.
The prevalence of IgG antibodies against CMV (p =
0.008), Chlamydia pneumoniae (p < 0.0001), and H.
pylori (p < 0.0001) were higher in men with the meta-
bolic syndrome than healthy subjects.
The prevalence of IgG antibodies against HSV-1 (p =
0.003), Chlamydia pneumoniae (p < 0.0001), and H.
pylori (p = 0.005) were higher in women with the meta-
bolic syndrome than healthy subjects.
Table 1 shows unadjusted odds ratio (95% C.I) between
metabolic syndrome and four infectious agents.
In multiple logistic regression analysis, of the infectious
agents, CMV [OR = 1.81 (1.05–3.10); p = 0.03], H. pylori
[OR = 1.50 (1.12–2.00); p = 0.007] and Chlamydia pneu-
moniae [OR = 1.69 (1.27–2.25); p < 0.0001] showed a
significant association with the metabolic syndrome in
men and HSV-1 [OR = 1.95 (1.22–3.11); p = 0.005], H.
pylori [OR = 1.45 (1.09–1.94); 0.01] and Chlamydia
pneumoniae [OR = 1.65 (1.23–2.21); p = 0.001] in
women.
Table 1: Unadjusted odd ratios (95% CI) and the prevalence of IgG antibodies against HSV-1, Chlamydia pneumoniae, HSV-1 and H. 
pylori among men & women with and without the metabolic syndrome; the Persian Gulf Healthy Heart Study
Male Female
Metabolic Syndrome Healthy O.R* C.I† p value Metabolic Syndrome Healthy O.R C.I p value
HSV-1‡ 84.2% 83.3% 1.06 0.73–1.54 N.S 92.1% 85.3% 2.01 1.27–3.16 0.003
CMV§ 94.3% 89.2% 1.99 1.121–3.27 0.007 94.8% 93.6% 1.23 0.7–2.15 N.S
Chlamydia pneumoniae 51.9% 37.8% 1.77 1.34–2.32 0.0001 42.2% 30.0% 1.69 1.28–2.23 0.0001
H. pylori** 67.9% 56.6% 1.62 1.23–2.13 0.001 64.4% 55.1% 1.47 1.12–1.92 0.004
* Odds Ratio
† Confidence Interval
‡ Herpes simplex virus type 1
§ Cytomegalovirus
**Helicobacter pyloriCardiovascular Diabetology 2006, 5:25 http://www.cardiab.com/content/5/1/25
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Discussion
The metabolic syndrome, which occurs very frequently in
our population, had a significant association with chronic
viral and bacterial infectious agents. To our knowledge,
this is the first population-based report of an association
of seropositivity of infectious agents with the metabolic
syndrome. The common features of these chronic infec-
tious agents are their contribution to inflammation and
promotion of atherosclerosis [6].
Infection, inflammation and the metabolic syndrome
Endothelial dysfunction was identified both in the exper-
iment and in patients after herpes virus simplex 1 infec-
tion, or Helicobacter pylori infection. However, it is not
clear whether it is always caused by direct specific activity
of a given pathogen or whether it is a result of inflamma-
tory cytokines activity, heat shock protein activity, or CRP
activity [9,10]. Individuals infected with multiple patho-
gens such as HSV-1, HSV-2, CMV and H. pylori have high
C-reactive protein levels (markers of inflammation) and
the greatest relative risk for coronary artery disease [11].
Thus, pathogens might contribute to the atherosclerotic
process by promoting inflammatory response.
All of the characteristics of metabolic syndrome are also
modestly associated with elevated levels of CRP. Moreo-
ver, CRP levels correlate with other components of the
metabolic syndrome that are not easily measured in clini-
cal practice, including fasting insulin, microalbuminuria,
and impaired fibrinolysis [12]. A recent study evaluated
interrelationships between CRP, the metabolic syndrome,
and incident cardiovascular events among 14719 appar-
ently healthy women, 24% of whom had the metabolic
syndrome, who were followed-up for an 8-year period for
myocardial infarction, stroke, coronary revascularization,
or cardiovascular death [13]. Although CRP levels are
related strongly to insulin resistance, it is difficult to con-
clude if low-grade inflammation induces insulin resist-
ance and the metabolic syndrome or is a consequence. A
reasonable proposal is that an imbalance in favor of pro-
inflammatory cytokines from adipose tissue and other
sources triggers CRP secretion. This in turn can exacerbate
mild insulin resistance and result in accentuation of other
metabolic abnormalities that constitute the metabolic
syndrome [5].
Chronic subclinical inflammation is increasingly recog-
nized as a part of the insulin resistance syndrome [14,15].
Dysregulation of the inflammatory axis predicts the devel-
opment of insulin resistance and type 2 diabetes mellitus.
Insulin resistance and another inflammatory state, athero-
sclerosis, share similar pathophysiological mechanisms,
mainly due to the actions of the two major proinflamma-
tory cytokines, TNF-alpha and IL-6 [16].
Taking into account the alleged common inflammatory
venue of these conditions, Fisman et al [17] hypothesized
that the effects of the interleukins on both disorders
would probably moving in the same direction-regardless
if harmful, favorable or neutral.
Proinflammatory cytokines and insulin resistance
TNF-alpha-induced insulin resistance has received much
recent attention [18]. Even though predominantly an
inflammatory cytokine, it has been implicated in confer-
ring insulin resistance in peripheral tissues in a number of
different disease states associated with elevated systemic
TNF-alpha levels, such as obesity, cancer, and infection
[19]. Chronic exposure of adipocytes to low concentra-
tions of TNF-alpha strongly inhibits insulin-stimulated
glucose uptake. Concurrently, TNF-alpha treatment
causes a moderate decrease in the insulin-stimulated auto-
phosphorylation of the insulin receptor (IR) and a dra-
matic decrease in the phosporylation of IR substrate 1, the
major substate of the IR in vivo [20]. Thus, TNF-alpha
directly interferes with the signaling of insulin through its
receptor and consequently blocks biological actions of
insulin.
A tight correlation between IL-6 and CRP exists; such a
correlation dose not exists for other cytokines. Two
important acute phase proteins, CRP and fibrinogen, have
IL-6 response elements in the promoter regions of their
genes. IL-6 is believed to be the main driver of CRP release
from hepatocytes [21]. IL-6 plasma levels are significantly
increased in murine and human insulin resistance, and
obesity [22]. Pickup et al showed increased levels of IL-6
in persons with more than two features of the metabolic
syndrome [23].
Unifying hypothesis
Therefore, chronic inflammation and increase in CRP
level are the common pathways in the metabolic syn-
drome and infectious agents for promotion of atheroscle-
rotic process. But what is the reason for the association of
HSV-1, CMV, H. pylori and Chlamydia pneumoniae and
the metabolic syndrome, as we observed in this study.
According to a unifying hypothesis, HSV-1, CMV, H.
pylori and Chlamydia pneumoniae induce production of
proinflammatory cytokines, such as TNF-alpha and IL-6
which are leading to chronic subclinical inflammation,
insulin resistance and the metabolic syndrome.
Limitations
This population-based study showed evidence for the
existence of an inflammatory link between HSV-1, CMV,
H. pylori and Chlamydia pneumoniae and the occurrence
of the insulin resistance dyslipidemic syndrome com-
monly known as the "metabolic syndrome". However,
further studies are needed to confirm our data and eluci-Cardiovascular Diabetology 2006, 5:25 http://www.cardiab.com/content/5/1/25
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date the pathogenic mechanisms underlying metabolic
syndrome-infections associations. Our study has some
limitations. As with any cross-sectional study design, there
is the possibility of unmeasured confounding. A consist-
ent limitation of our seroepidemiologic study, however, is
the uncertain correlation between serologic criteria and
the presence of endovascular infection. We conducted our
study in a large random population and used seropositiv-
ity as a marker for infections; however it has the advantage
of clinical applicability, but the assessment of infection
status based on serology without further clinical or labo-
ratory characterization is subject to diagnostic inaccura-
cies, especially if seropositivity is common because of the
widespread distribution of the incriminated microorgan-
ism. But the knowledge of how interaction between met-
abolic and chronic infectious pathways occurs will be
useful in future therapeutic strategies. The effective
administration of anti-inflammatory agents, vaccines and
antibiotics in the treatment of insulin resistance and
atherosclerosis is only the beginning of a promising
approach in the management of the metabolic syndrome.
Conclusion
The metabolic syndrome, which occurs very frequently in
the general population, has a significant association with
prior infection with Chlamydia pneumoniae, Helico-
bacter pylori, cytomegalovirus and herpes simplex virus
type 1. Hypothesis about participation of infection in
pathogenesis of metabolic syndrome should be investi-
gated.
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